Brought to you by 
ViroPharma gets rights to Intellect’s Friedreich’s ataxia candidate OX1
23 Sep 2014
Executive Summary
Intellect Neurosciences Inc. (oxidative stress-related conditions) has licensed rare disease company ViroPharma Inc. exclusive global rights to its issued patents and patent applications related to OX1 (indole-3-propionic acid (IPA); also known as Oxigon). As a result, ViroPharma has rights to develop, manufacture, distribute, and commercialize therapeutics containing OX1 for the treatment, management, or prevention of any indication protected by Intellect’s IP, which was originally discovered by scientists at New York University and the University of South Alabama’s South Alabama Medical Science Foundation.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ViroPharma gets rights to Intellect’s Friedreich’s ataxia candidate OX1
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice